Literature DB >> 24277215

Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System.

R C Sawyer1, R L Stolfi, S Spiegelman, D S Martin.   

Abstract

The effect of uridine on the incorporation of 5-fluorouracil into RNA and the inhibition of DNA synthesis by the FdUMP block of thymidylate synthetase was studied in the CD8F1 murine mammary carcinoma system. The administration of exogenous uridine resulted in about a one third reduction of 5-fluorouracil in RNA of tumor and normal tissues. However, unlike thymidine, uridine was unable to reverse the early, partial inhibition of DNA synthesis. The amount of fluorouridine nucleotides and (5-fluorouracil)RNA formed in various tissues correlates with the level of orotate phosphoribosyl transferase activity suggesting that the major pathway for activation of 5-fluorouracil to nucleotide form in these tissues is via phosphoribosyl transferase. Enzyme preparations from three different murine tumors convert about 15 times as much 5-fluorouracil to FUMP as they do uracil to UMP. In contrast, the ratio of FUMP to UMP formed in enzyme preparations from gut and bone marrow is lower, 2-6 fold. However, in none of these tissues was the in vitro conversion of 5-fluorouracil to FUMP or incorporation into RNA substantially inhibited by uracil. Examination of tumor, gut and bone marrow uridine nucleotide pools showed that the thymidine-uridine-5-fluorouracil schedule does increase uridine nucleotide pools. Thus, the reduction in 5-fluorouracil in RNA is probably not due to inhibition of the conversion of 5-fluorouracil to FUMP by uracil (derived from phosphorylase cleavage of uridine) but, rather, is probably due to the elevated levels of UTP. We conclude that the protection from 5-fluorouracil toxicity afforded by the addition of uridine is due to the reduction in 5-fluorouracil in RNA rather than by reversal of the FdUMP block on thymidylate synthetase.

Entities:  

Year:  1984        PMID: 24277215     DOI: 10.1023/A:1016351330832

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.

Authors:  J D Moyer; R E Handschumacher
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

2.  Synthesis of 5-fluorouridine 5'-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice.

Authors:  P Reyes; T C Hall
Journal:  Biochem Pharmacol       Date:  1969-10       Impact factor: 5.858

3.  Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

Authors:  S Fujii; K Ikenaka; M Fukushima; T Shirasaka
Journal:  Gan       Date:  1978-12

4.  The incorporation of uridine label into the RNA of mouse embryo cells does not always reflect the labelling of the major cellular UTP pool.

Authors:  P W Piper
Journal:  FEBS Lett       Date:  1981-08-31       Impact factor: 4.124

5.  Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.

Authors:  S Spiegelman; R Nayak; R Sawyer; R Stolfi; D Martin
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

Review 6.  An overview of thymidine.

Authors:  D S Martin; R L Stolfi; R C Sawyer; R Nayak; S Spiegelman; C W Young; T Woodcock
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

7.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice.

Authors:  D S Martin; R L Stolfi; R C Sawyer; S Spiegelman; C W Young
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

9.  Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.

Authors:  C E Myers; R C Young; B A Chabner
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

Review 10.  Structural features of the phosphoribosyltransferases and their relationship to the human deficiency disorders of purine and pyrimidine metabolism.

Authors:  W D Musick
Journal:  CRC Crit Rev Biochem       Date:  1981
View more
  4 in total

1.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; J Lankelma; A Leyva; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.